Contrary to our findings, worse patient survival for patients with ASS1 loss could be observed in other entities, for example, gastric cancer, hepatocellular carcinoma, or myxofibrosarcoma [6,24,25]. This evidence concerns the gene ASS1 and myxofibrosarcoma.